116.50 -0.31 (-0.27%)
Pre-Market: 8:01AM EDT
|Bid||114.92 x 800|
|Ask||119.48 x 3000|
|Day's Range||116.48 - 117.96|
|52 Week Range||81.65 - 132.13|
|Beta (3Y Monthly)||0.44|
|PE Ratio (TTM)||18.98|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||2.58 (2.20%)|
|1y Target Est||124.57|
Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Eli Lilly & Co. said its lower-priced Insulin Lispro Injection is now available for order in pharmacies, per vial or in a package of five KwikPens. The drug giant said Lispro Injection's list price is 50% lower than its identical branded Humalog U-100. Lispro Injection has a list price of $137.35 per vial and $265.20 for a package of five KwikPens. "Because most insurance plans provide affordable copays for chronic medicines that are much lower than list price, people should ask their pharmacist whether Insulin Lispro Injection or Humalog is the lower-cost option for them," Lilly said in a statement. The stock, which was still inactive in premarket trade, has edged up 0.7% year to date, while the SPDR Health Care Select Sector ETF has gained 3.1% and the S&P 500 has rallied 14.3%.
A half-price version of Eli Lilly's popular Humalog insulin is now available, following the company's promise in March to offer diabetics a more affordable option amid fierce criticism of soaring insulin prices.
INDIANAPOLIS, May 22, 2019 /PRNewswire/ -- Eli Lilly and Company's (LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection has a 50 percent lower list price than its identical medicine, Humalog® U-100 (insulin lispro injection) and is available in both a vial and KwikPen®. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog.
Array stock popped in high volume Tuesday after its colon cancer treatment showed promise in a Phase 3 study. Array stock hit a record high and closed well above its 50-day moving average.
INDIANAPOLIS, May 21, 2019 /PRNewswire/ -- In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease. Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. In this study, patients with moderately- to severely active Crohn's disease were randomized to receive either placebo or one of three doses of mirikizumab, which is an investigational antibody that targets the p19 subunit of interleukin 23.
After upgrading Pfizer (NYSE:PFE) to "Outperform" in January and raising its price target on Pfizer stock to $48 in May, one would think there's nothing else Credit Suisse could so to bolster its bullish case, but there is.Source: Kojach Via FlickrFollowing a meeting with the pharmaceutical giant's top brass just a few days ago, on Thursday, Credit Suisse labeled PFE stock a "top pick." It was apparently one heck of a meeting.The specifics prompting the accolade weren't made crystal clear, though Credit Suisse did note that the company's prospects for new products was compelling. Translation: Whatever stoked Credit Suisse's fires is likely to be in the company's late-stage pipeline, which is admittedly more exciting than it has been in a long while.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Yield REITs to Buy (Even When the Market Tanks) A Brief Look at PfizerIt's not a story that needs a great deal of retelling. It was an unstoppable powerhouse when it had full patent protection of its erectile dysfunction drug Viagra and faced little competition. But, seeing the writing on the wall, the drugmaker allowed Teva Pharmaceutical Industries (NYSE:TEVA) to begin selling a generic version of the drug in 2017. In the meantime, consumer interest in ED drugs has broadly waned.Pfizer is about to lose ground with blockbuster neuropathic pain drug Lyrica too, which lost patent protection last year, threatening to quickly cut its $5 billion in annual sales in half once generic alternatives become available.It's the same story that plays out over and over within the pharmaceutical industry; these organizations must constantly replenish their portfolios with patent-protected drugs, or risk losing ground.It's something Pfizer hasn't done especially well in recent years.Although Pfizer stock has made reliable if choppy progress since turning around with all other stocks in 2009, revenue growth hasn't been overwhelming. The $53.9 billion in sales generated over the course of the past four reported quarters was not remarkable better than the $52.7 billion figure from a year earlier."Pfizer has been working through a dark period with extensive patent expirations," Credit Suisse analyst Vamil Divan said in late January. "That period is now nearing an end." Solid PipelineWhat Pfizer told Credit Suisse at the meeting remains veiled, though when Divan upgraded Pfizer stock early this year he explicitly noted opportunities for several cancer and autoimmune disease drugs along with vaccinations.Two of the drugs Divan had in mind are Vyndaqel and Vyndamax (though they're actually different doses of the same molecule), which combats the buildup for amyloid in the heart.Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) already make similar rival drugs, but their versions are considerably more expensive. Divan foresees peak sales of $2 billion for Vyndaqel, but is willing to entertain a number "significantly larger than that if Pfizer is able to commercialize it successfully."Pfizer has also partnered with Eli Lilly (NYSE:LLY) on the development of a non-opioid arthritis treatment called tanezumab, another one of the 15 game-changing drugs Pfizer believes could be brought to the market within the next five years.Some analysts are looking for modest peak sales of around $500 million, although Cantor Fitzgerald analyst Louise Chen thinks tanezumab could prove to a multi-billion dollar opportunity to replace a significant piece of the existing opioid market.In the meantime, Pfizer aims to widen the uses of already-marketable drugs like Ibrance, Eliquis, and Xeljanz.Ibrance has already become something of a wonder drug. Already approved as a therapy for multiple forms of breast cancer and generating revenue of $4.1 billion last year, expanded labeling could translate into peak annualized revenue of $8 billion before the treatment hits its ceiling.Eliquis (or Apixaban) for blood clots, co-marketed with Bristol-Myers Squibb (NYSE:BMY), and arthritis/ulcerative colitis therapy Xeljanz generated nearly $3.5 billion and more than $1.7 billion worth of revenue for Pfizer last year, respectively, yet both are also in trials for new uses after having proven they're safe and effective.All told, Pfizer's got 23 phase 3 trials underway right now. All of them look promising; most of them appear to have blockbuster potential. Looking Ahead for Pfizer StockIt was self-serving to be sure when CEO Albert Bourla proclaimed in January that Pfizer is sitting on its "greatest pipeline ever."But that doesn't mean he's wrong.Granted, the deterioration of Pfizer stock since December's peak (PFE stock been performing completely contrary to the market for months) says investors don't exactly believe Bourla. The crowd has understandably become a "show me first" mob, willing to wait on the sidelines for proof that the pipeline can do all the company suggests it can do.Credit Suisse's Divan may have the right idea though. The time to step into a great prospect is when its stock is down because the majority of investors aren't convinced and analysts are collectively lukewarm because they're unable to see more than a few months down the road.That's certainly Pfizer stock right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock appeared first on InvestorPlace.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
INDIANAPOLIS , May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Christi Shaw , president of Lilly Bio-Medicines, ...
Lung cancer highlights to include the first presentation of RELAY results and additional findings from KEYNOTE-189 Lilly to share data from Phase 3 ANNOUNCE trial in people with advanced soft tissue sarcoma ...